Global Scleroderma Treatment Market 2017-2021

This market research study identifies AstraZeneca, F. Hoffmann-La Roche, GlaxoSmithKline, and Pfizer as the leading players in the global scleroderma treatment market. A comprehensive analysis of this market is also presented by drug class (anti-inflammatory drugs, immunosuppressants, PDE5 inhibitors, calcium channel blockers, and others) and by geography (the Americas, APAC, and EMEA).

Overview of the global scleroderma treatment market

According to Technavio’s market research report, the global scleroderma treatment market will grow at a CAGR of more than 7% during the forecast period. One of the key factors that will stimulate the growth of this market during the forecast period is the increased funding for research and developmental activities. The rising unmet needs of the scleroderma treatment is compelling the government and non-government organizations to invest more in R&D projects that are focused on specific symptoms and features of scleroderma. Scleroderma Research Foundation is one of the organizations that supports leading innovators and scientists in various fields by investing in research projects. Stanford University is already working on a new project that focuses on the comparative study of gender-specific gene regulatory networks in scleroderma patients and healthy volunteers. Such studies help in the identification of the possible source of cancer and autoimmune disorders and will in turn, enable innovators to come up with better scleroderma treatments.

Stem cell transplants can provide sustained remissions in patients with severe autoimmune diseases such as lupus, rheumatoid arthritis, juvenile arthritis, and multiple sclerosis. The autologous blood cell stem cell transplants can significantly improve the survival rate of patients suffering from scleroderma. This will increase the adoption of stem cell therapy for the treatment of scleroderma and according to this industry research report, this will be one of the key trends that will gain traction in the scleroderma treatment market in the coming years.

Competitive landscape and key vendors

The scleroderma treatment market is highly fragmented due to the presence of many key vendors. These vendors are increasingly competing against each other based on factors such as aggressive pricing and new indications. Vendors are taking efforts to address the unmet medical needs by providing novel therapeutics. They are also focusing on the development of drugs in new route of administrations (ROAs) such as topical patches. To improve their market positions, the players in this marketspace also focus on adopting strategies such as M&As and distribution through partnerships.

Key vendors in this market are -

• AstraZeneca
• F. Hoffmann-La Roche
• GlaxoSmithKline
• Pfizer

Other prominent vendors in the market include Amgen, Bayer AG, Boehringer Ingelheim, Biogen, CELGENE, Corbus Pharmaceuticals, Johnson & Johnson, Merck, Novartis, and Sanofi.

Segmentation by drug class and analysis of the scleroderma treatment market

• Anti-inflammatory drugs
• Immunosuppressants
• PDE5 inhibitors
• Calcium channel blockers

Inflammations in patients who are suffering from scleroderma are treated with anti-inflammatory drugs such as nonsteroidal anti-inflammatory drugs (NSAIDs) or corticosteroids. The conventional type of inflammation causes myositis (inflammation in the muscles), serositis (inflammation of the serous membrane), and arthritis (inflammation in the joints). Owing to the increasing number of patient assistance programs, the anti-inflammatory drugs segment accounted for the major shares of the market during 2016. Analysts predict that this segment will continue to contribute for the maximum market shares during the next four years as well and this will attribute to the rising demand for prednisone and ibuprofen.

Segmentation by geography and analysis of the scleroderma treatment market

• Americas
• APAC
• EMEA

With the high prevalence rate of scleroderma in countries such as the US, the Americas accounted for the majority market share during 2016. The availability of the treatment for scleroderma will increase during the forecast period due to the increasing investments from the government towards R&D activities for rare diseases. Additionally, several government and non-government organizations in this region are also taking initiatives to support scleroderma patients.

Key questions answered in the report include

• What will the market size and the growth rate be in 2021?
• What are the key factors driving the global scleroderma treatment market?
• What are the key market trends impacting the growth of the global scleroderma treatment market?
• What are the challenges to market growth?
• Who are the key vendors in the global scleroderma treatment market?
• What are the market opportunities and threats faced by the vendors in the global scleroderma treatment market?
• What are the trending factors influencing the market shares of the Americas, APAC, and EMEA?
• What are the key outcomes of the five forces analysis of the global scleroderma treatment market?

Technavio also offers customization on reports based on specific client requirement